APA (7th ed.) Citation

Zhang, M., Wang, S., Wilffert, B., Tong, R., Soolingen, D., Hof, S., & Alffenaar, J. (2018). The association between the NAT2 genetic polymorphisms and risk of DILI during anti‐TB treatment: A systematic review and meta‐analysis. British journal of clinical pharmacology, 84(12), 2747-2760. https://doi.org/10.1111/bcp.13722

Chicago Style (17th ed.) Citation

Zhang, Min, Shuqiang Wang, Bob Wilffert, Rongsheng Tong, Dick Soolingen, Susan Hof, and Jan‐Willem Alffenaar. "The Association Between the NAT2 Genetic Polymorphisms and Risk of DILI During Anti‐TB Treatment: A Systematic Review and Meta‐analysis." British Journal of Clinical Pharmacology 84, no. 12 (2018): 2747-2760. https://doi.org/10.1111/bcp.13722.

MLA (9th ed.) Citation

Zhang, Min, et al. "The Association Between the NAT2 Genetic Polymorphisms and Risk of DILI During Anti‐TB Treatment: A Systematic Review and Meta‐analysis." British Journal of Clinical Pharmacology, vol. 84, no. 12, 2018, pp. 2747-2760, https://doi.org/10.1111/bcp.13722.